Survodutide SYNCHRONIZE-1: 16.6% Weight Loss in Phase 3 Dual Agonist Trial
Boehringer Ingelheim and Zealand Pharma announced detailed Phase 3 SYNCHRONIZE-1 results at the American Diabetes Association's 86th Sc...
ADA 86th Scientific Sessions 2026: Outcomes Summary
The American Diabetes Association's 86th Scientific Sessions closed Monday, June 8, 2026 in New Orleans after four days of late-breakin...
GLP-1s and Cancer Risk: What ASCO 2026 Showed
The 2026 American Society of Clinical Oncology Annual Meeting (ASCO 2026), held May 29 - June 2 in Chicago, featured multiple presentat...
ADA 86th Scientific Sessions 2026: What to Watch in Cardiometabolic Research
The American Diabetes Association's 86th Scientific Sessions take place June 5-8, 2026 in New Orleans — the largest annual diabetes res...
Retatrutide TRIUMPH-1 Phase 3 Results: Up to 30% Weight Loss
On May 21, 2026, Eli Lilly announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial of Retatrutide in adults with ob...
FDA PCAC to Review Peptide Compounding: What the July 2026 Hearing Means
On April 16, 2026, the U.S. Food and Drug Administration (FDA) published a Federal Register notice announcing that the Pharmacy Compoun...